Sharon Cload is Vice President, Discovery Biotherapeutics, at Bristol Myers Squibb, where her team works across several therapeutic areas including immunology, cardiovascular, fibrosis, and oncology. Sharon is part of the team that launched Bristol Myers Squibb’s new research site in Kendall Square in 2018, and she took on her current role in November 2019, after Bristol Myers Squibb’s acquisition of Celgene. She joined Bristol Myers Squibb in 2008 and led the evolution of the core biologics discovery platforms at their Adnexus site in Waltham, as well as integration of that group into the broader discovery organization. Sharon has enjoyed being part of the vibrant Cambridge life sciences ecosystem throughout her career. Her prior roles in biotech settings cultivated her interest in novel discovery technologies. She led the aptamer discovery team at Archemix Corp. and developed affinity-based screening platforms for small molecules at Scriptgen Pharmaceuticals. She was a post-doctoral fellow with Peter Schultz at the University of California, Berkeley and earned her Ph.D. in Bio-Organic Chemistry with Alanna Schepartz at Yale University.